Minoxidil is not a new medicine, in fact it was the first medication approved by the US FDA to treat hair loss in 1996. After decades of use, topical minoxidil has proven to be a safe and effective treatment for hair loss. There are different strengths and preparations available – the 5% is proven to be most effective. Minoxidil is the active ingredient in Regaine and many different brands are available.
Side effects are rare and most commonly include shedding of smaller miniaturised hairs over the first few months of usage (a sign the Minoxidil is working – this settles down over a few months of continuous usage), and scalp irritation.
Scalp irritation is commonly linked to Minoxidil preparations containing Propylene Glycol (PG). Some patients can also complain of itchy flaky scalp which may be unrelated and there are other more likely causes of these symptoms (such as contact dermatitis, allergic contact dermatitis, or an exacerbation of seborrheic dermatitis) and may not be directly caused by minoxidil. Additionally, there is a clinical benefit as propylene-glycol-free minoxidil has been shown to have improved permeability over Minoxidil containing propylene glycol.
Sons' Minoxidil does not contain Propylene Glycol and so should cause less scalp irritation than many other preparations. With our convenient actuator, the Minoxidil reaches the scalp more directly and easier than other preparations such as the 5% foam. There is also the benefit that the actuator removes the mess of different liquids that can run down the scalp during application.
So, why chose Sons Minoxidil; it causes less scalp irritation, it’s easier to apply and is more easily absorbed than many other preparations.
If you need further evidence, here’s some studies backing up from this blog.
Source: Contemporary Clinic
Source: The Dermatologist
Source: Taylor & Francis Online
Scheman AJ, West DP, Hordinksy MK, Osburn AH, West LE. Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients. Contact Dermatitis. 2000;42(4):241.